Endocrinology, Vol 124, 2645-2647, Copyright © 1989 by Endocrine Society

ARTICLES

A synthetic analogue of vitamin D3, 22-oxa-1 alpha,25-dihydroxyvitamin D3, is a potent modulator of in vivo immunoregulating activity without inducing hypercalcemia in mice

J Abe, Y Takita, T Nakano, C Miyaura, T Suda and Y Nishii
Research Laboratories, Chugai Pharmaceutical Co. Ltd., Tokyo, Japan.

The in vivo immunoregulating activity and the hypercalcemic action of 4 synthetic analogues of vitamin D3 with an oxygen atom in the side chain were compared with those of 1 alpha,25-dihydroxyvitamin D3 [1 alpha,25(OH)2D3] in mice. Oral administration of these vitamin D3 compounds augmented the primary immune response, induced by immunization with a suboptimal number of sheep erythrocytes, without inducing hypercalcemia. The order of the in vivo potency to induce the immune response was 22-oxa-1 alpha,25(OH)2D3 greater than 1 alpha,25(OH)2D3 not equal to 20-oxa-1 alpha,25(OH)2D3 not equal to 22- oxa-1 alpha(OH)D3 greater than 1 alpha(OH)D3 not equal to 20-oxa-1 alpha(OH)D3. 22-Oxa-1 alpha,25(OH)2D3 was about 50 times more potent than 1 alpha,25(OH)2D3 in inducing the in vivo primary immune response, but the former was only 1/100 as active as the latter in inducing hypercalcemia. These results suggest that the immunoregulating activity of vitamin D compounds can be separated structurally from their hypercalcemic action in vivo.

This article has been cited by other articles:

				D. D. Moore, S. Kato, W. Xie, D. J. Mangelsdorf, D. R. Schmidt, R. Xiao, and S. A. Kliewer International Union of Pharmacology. LXII. The NR1H and NR1I Receptors: Constitutive Androstane Receptor, Pregnene X Receptor, Farnesoid X Receptor {alpha}, Farnesoid X Receptor beta, Liver X Receptor {alpha}, Liver X Receptor beta, and Vitamin D Receptor Pharmacol. Rev., December 1, 2006; 58(4): 742 - 759. [Abstract] [Full Text] [PDF]

				M. Kamao, S. Tatematsu, S. Hatakeyama, K. Ozono, N. Kubodera, G. S. Reddy, and T. Okano Two Novel Metabolic Pathways of 22-Oxacalcitriol (OCT). C-25 DEHYDRATION AND C-3 EPIMERIZATION AND BIOLOGICAL ACTIVITIES OF NOVEL OCT METABOLITES J. Biol. Chem., January 10, 2003; 278(3): 1463 - 1471. [Abstract] [Full Text] [PDF]

				S. Huerta, R. W. Irwin, D. Heber, V. L. W. Go, H. P. Koeffler, M. R. Uskokovic, and D. M. Harris 1{alpha},25-(OH)2-D3 and Its Synthetic Analogue Decrease Tumor Load in the Apcmin Mouse Cancer Res., February 1, 2002; 62(3): 741 - 746. [Abstract] [Full Text] [PDF]

				H. F. DELUCA and M. T. CANTORNA Vitamin D: its role and uses in immunology FASEB J, December 1, 2001; 15(14): 2579 - 2585. [Abstract] [Full Text] [PDF]

				K. Makibayashi, M. Tatematsu, M. Hirata, N. Fukushima, K. Kusano, S. Ohashi, H. Abe, K. Kuze, A. Fukatsu, T. Kita, et al. A Vitamin D Analog Ameliorates Glomerular Injury on Rat Glomerulonephritis Am. J. Pathol., May 1, 2001; 158(5): 1733 - 1741. [Abstract] [Full Text] [PDF]

				S. Masuda, V. Byford, R. Kremer, H. L. J. Makin, N. Kubodera, Y. Nishii, A. Okazaki, T. Okano, T. Kobayashi, and G. Jones In Vitro Metabolism of the Vitamin D Analog, 22-Oxacalcitriol, Using Cultured Osteosarcoma, Hepatoma, and Keratinocyte Cell Lines J. Biol. Chem., April 12, 1996; 271(15): 8700 - 8708. [Abstract] [Full Text] [PDF]